Forigerimod

OC(C=C1)=CC=C1C[C@H](NC([C@H](C(C)C)NC([C@H](CCSC)NC([C@@H](NC([C@H]([C@@H](C)CC)NC([C@@H](N)CCCNC(N)=N)=O)=O)CC2=CN=CN2)=O)=O)=O)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](COP(O)(O)=O)C(NCC(N[C@@H](CCCCN)C(N3[C@@H](CCC3)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@H](C(N[C@@H](C)C(N[C@H](C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCC(O)=O)C(N[C@H](C(O)=O)CC4=CC=C(C=C4)O)=O)=O)=O)CC5=CC=CC=C5)=O)=O)CC6=CC=C(C=C6)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O

[1]Aikaterini Thanou, et al. Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys. |[2]Sean Robinson, et al. Potential for Antigen-Specific Tolerizing Immunotherapy in Systematic Lupus Erythematosus. Front Immunol. 2021 Jul 16;12:654701.|[3]Robert Zimmer, et al. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis. 2013 Nov;72 (11) :1830-5.|[4]Baihui Li, et al. Rescue of autophagy and lysosome defects in salivary glands of MRL/lpr mice by a therapeutic phosphopeptide. J Autoimmun. 2018 Jun;90:132-145.